Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Novo Nordisk is growing its India-based global business services to fill out vertical stacks, expand horizontal functions, ...
Biohacker Bryan Johnson’s sleep hacks have gone viral but we're asking the experts to find out exactly how effective these ...
Verywell Mind on MSN11h
How the Progression of Alzheimer's Changes YouHow effective will this be? How will they respond to this therapy?’ And, in that hopeful stage, we tend to offer a lot more ...
More than 33 million people in the U.S. have a serious and potentially life-threatening food allergy, according to Food ...
Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.
A Chinese biotech that became popular by co-developing an anti-Covid drug has filed for a Hong Kong stock market listing.
The average drug takes 10+ years and $2.3B to bring to market—with a 90% failure rate in clinical trials. AI is rewriting this equation. By 2025, AI-driven drug discovery is projected to slash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback